| __timestamp | Alnylam Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 302156000 |
| Thursday, January 1, 2015 | 60610000 | 402271000 |
| Friday, January 1, 2016 | 89354000 | 476593000 |
| Sunday, January 1, 2017 | 199365000 | 554336000 |
| Monday, January 1, 2018 | 382359000 | 604353000 |
| Tuesday, January 1, 2019 | 479005000 | 680924000 |
| Wednesday, January 1, 2020 | 588420000 | 737669000 |
| Friday, January 1, 2021 | 620639000 | 759375000 |
| Saturday, January 1, 2022 | 770658000 | 854009000 |
| Sunday, January 1, 2023 | 795646000 | 937300000 |
| Monday, January 1, 2024 | 975526000 | 1009025000 |
Unlocking the unknown
In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. have demonstrated distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive expansion and strategic investments. In contrast, BioMarin's expenses grew by about 210%, indicating a more measured approach.
Alnylam's expenses peaked in 2023, reaching nearly 800% of their 2014 levels, showcasing its commitment to scaling operations. Meanwhile, BioMarin maintained a steady increase, with expenses rising to over 300% of their initial value by 2023. This divergence highlights differing strategic priorities: Alnylam's focus on rapid growth versus BioMarin's emphasis on sustainable development. Understanding these trends offers valuable insights into the financial strategies of leading biopharma companies.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.